(Q34631613)

3 August 2017

1 reference

title

Endothelin in health and disease: endothelin receptor antagonists in the management of pulmonary artery hypertension (English)

1 reference

3 August 2017

Nick H S Kim

1

1 reference

3 August 2017

Lewis J Rubin

series ordinal

2

1 reference

3 August 2017

publication date

1 January 2002

1 reference

Journal of Cardiovascular Pharmacology and Therapeutics

3 August 2017

published in

1 reference

3 August 2017

volume

7

1 reference

3 August 2017

issue

1

1 reference

3 August 2017

page(s)

9-19

1 reference

A novel potent vasoconstrictor peptide produced by vascular endothelial cells

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F107424840200700I102

Endothelial cell responses to hypoxic stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840200700I102

Mitogenic actions of endothelin-1 and epidermal growth factor in cultured airway smooth muscle.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840200700I102

Endothelins stimulate aldosterone secretion from dispersed rat adrenal zona glomerulosa cells, acting through ETB receptors coupled with the phospholipase C-dependent signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840200700I102

EndothelinB (ETB) receptor-activated potentiation of cholinergic nerve-mediated contraction in human bronchus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840200700I102

The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840200700I102

Endothelin: an endothelium-derived vasoactive peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840200700I102

Different electrical responses to vasoactive agonists in morphologically distinct smooth muscle cell types

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840200700I102

Subcellular mechanisms of endothelin action in vascular system

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840200700I102

21 January 2018

Endothelin antagonists

1 reference

https://api.crossref.org/works/10.1177%2F107424840200700I102

Role of endothelin in the increased vascular tone of patients with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840200700I102

Effects of Ro 47-0203 on endothelin-1 and sarafotoxin S6c-induced contractions of human bronchus and guinea-pig trachea

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840200700I102

Acute pro-inflammatory actions of endothelin-1 in the guinea-pig lung: involvement of ETA and ETB receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840200700I102

Clinical experience with endothelin receptor antagonists in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840200700I102

EndothelinB receptor-mediated contraction in human pulmonary resistance arteries

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840200700I102

Expression of endothelin-1 in the lungs of patients with pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840200700I102

Pathophysiology of endothelin in the cardiovascular system

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840200700I102

Endothelins in health and disease: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840200700I102

Endothelins in chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840200700I102

Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840200700I102

Tissue endothelin-converting enzyme activity correlates with cardiovascular risk factors in coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840200700I102

Hemodynamic effects of Bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840200700I102

Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840200700I102

Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840200700I102

Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840200700I102

Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840200700I102

High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840200700I102

Primary pulmonary hypertension. A national prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840200700I102

Pulmonary hypertension: diagnostics and therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840200700I102

Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840200700I102

The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840200700I102

Acute pulmonary vasodilatory properties of amlodipine in humans with pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840200700I102

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840200700I102

Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840200700I102

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840200700I102

Endothelin System–Dependent Cardiac Remodeling in Renovascular Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840200700I102

10.1177/107424840200700I102

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference